Caladrius Biosciences Inc. (CLBS) Has Jumped To A New High On FDA News
Caladrius Biosciences Inc. (CLBS) announced Tuesday that it has received a regenerative medicine advanced therapy designation from the FDA for its CD34+ cell therapy program for the treatment of refractory angina.
Source: RTTNews